Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.

We studied the effect of selegiline (deprenyl) treatment on the number of Lewy bodies and neuron counts in the substantia nigra in patients with Parkinson's disease (PD). The number of medial nigral neurons was greater and the number of Lewy bodies fewer in those PD patients who had been treated with selegiline in combination with levodopa as compared with patients who had received levodopa alone. This suggests that selegiline treatment may retard the death of nigral neurons, but alternative explanations, such as the reduction of levodopa dosage in selegiline-treated patients, are possible.

Parkinson's research / abstracts

 1.    Deprenyl  effect on cognitive functions in early Parkinson's 
 2.    Deprenyl  depression in Parkinson's disease
 3.    Deprenyl  stimulates biosynthesis of cytokines interleukin-1 & 6
 4.    Deprenyl  effect of MAO-B inhibitors on MPP+ toxicity
 5.    Deprenyl  modulates the decline of the dopamineric system
 6.    Deprenyl  possible mechanisms of action in Parkinson's 
 7.    Deprenyl  pharmacological basis of the beneficial effects
 8.    Deprenyl  improves visuo-motor control in early Parkinsonism
 9.    Deprenyl  delays disability in Parkinsonian patients
10.   Deprenyl  management of early Parkinson's disease
11.   Deprenyl  delays the onset of disability in Parkinsonian patients
12.   Deprenyl  and tocopherol antioxidative therapy of Parkinsonism